ClinicalTrials.gg
CompletedNCT02145234Updated Sep 7, 2017

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

A Phase 1 interventional study of BMS-986089 and Placebo matching with BMS-986089 in Healthy Adults, sponsored by Hoffmann-La Roche. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-07.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of single and multiple doses of BMS-986089 in healthy adult subjects.

Read the detailed description

Primary Purpose - other: Protocol designed to assess the safety, tolerability, immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-986089 in healthy subjects

Enrollment: Single ascending dose panels: 48 subjects, Multiple ascending dose panels: 96

Minimum age: 18 years (Elderly MAD Panel 65 years of age) Maximum age: 55 years (Elderly MAD Panel 70 years of age)

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Healthy subjects as determined by no deviation from normal medical history, physical examination, ECGs and clinical laboratory determinations
  • Men and women who are not of (ie, who are or Surgically sterile WOCBP) ages 21 to 55 years
  • Women must not be breastfeeding
  • Men who are sexually active with women of child bearing potential (WOCBP) must use any method with a failure rate of less than 1% per year

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness Any major surgery within 6 weeks of study drug administration
  • Any condition that will clearly require medical or surgical treatment during the period of study participation
  • Any bone trauma or bone surgery within 3 months of study drug administration
  • Known or suspected disorder
  • Donation of blood or plasma to a blood bank or in a clinical study (except at screening visit) within 6 weeks of study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    SAD Panel 1:BMS-986089/Placebo

    BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    SAD Panel 2:BMS-986089/Placebo

    BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    SAD Panel 3:BMS-986089/Placebo

    BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    SAD Panel 4:BMS-986089/Placebo

    BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    SAD Panel 5:BMS-986089/Placebo

    BMS-986089 in a single subcutaneous administration OR Placebo matching with BMS-986089 in a single subcutaneous administration

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    MAD Panel 1:BMS-986089/Placebo

    BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 multiple subcutaneous administrations weekly

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    MAD Panel 2:BMS-986089/Placebo

    BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    MAD Panel 3:BMS-986089/Placebo

    BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    MAD Panel 4:BMS-986089/Placebo

    BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    MAD Panel 5:BMS-986089/Placebo

    BMS-986089 in multiple subcutaneous administration every 2 weeks OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    MAD Panel 6:BMS-986089/Placebo

    BMS-986089 in multiple subcutaneous administrations weekly OR Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

  • Experimental
    MAD Panel 7:BMS-986089/Placebo

    BMS-986089 a single subcutaneous administrations weekly OR Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks

    Drug: BMS-986089 · Drug: Placebo matching with BMS-986089

Interventions

  • DrugPlacebo matching with BMS-986089
06

What researchers measure

Primary outcomes

  1. Safety endpoints, including incidence of Adverse Event (AEs), serious AEs, AEs leading to discontinuation or death, as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, and physical examinations

    Time frame: Single Ascending Dose (SAD) Phase 119 days

  2. Safety endpoints, including incidence of Adverse Event (AEs), serious AEs, AEs leading to discontinuation or death, as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, and physical examinations

    Time frame: Multiple Ascending Dose (MAD) phase 148 days

Secondary outcomes

  1. Maximum observed serum concentration (Cmax) for SAD and MAD

    Time frame: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

  2. Time of maximum observed serum concentration (Tmax) for SAD and MAD

    Time frame: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

  3. Serum concentration 168 h post dose (C(168H)) for SAD and MAD

    Time frame: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

  4. Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) for SAD

    Time frame: SAD phase: Day1 to Day 91

  5. Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) for SAD

    Time frame: SAD phase: Day1 to Day 91

  6. Apparent total body clearance (CLT/F) for SAD

    Time frame: SAD phase: Day1 to Day 91

  7. Volume of distribution of terminal phase (if IV and if multi-exponential decline) (Vz/F) for SAD

    Time frame: SAD phase: Day1 to Day 91

  8. Half life (T-Half) for SAD and MAD

    Time frame: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

  9. Serum concentration 336 h post dose (C(336H)) for SAD and MAD

    Time frame: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

  10. Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff_AUC) for MAD

    Time frame: MAD phase: Day 1 to Day 120

  11. Area under the concentration-time curve in one dosing interval (AUC(TAU)) for MAD

    Time frame: MAD phase: Day 1 to Day 120

  12. Degree of Fluctuation or Fluctuation Index (DF) for MAD

    Time frame: MAD phase: Day 1 to Day 120

  13. Average concentration over a dosing interval (Css-Avg) for MAD

    Time frame: MAD phase: Day 1 to Day 120

  14. AUC Accumulation Index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI AUC) for MAD

    Time frame: MAD phase: Day 1 to Day 120

  15. Cmax Accumulation Index; ratio of Cmax at steady-state to Cmax after the first dose (AI Cmax) for MAD

    Time frame: MAD phase: Day 1 to Day 120

  16. C(168H) Accumulation Index; ratio of C168H at steady-state to C168H after the first dose (AI C168H) for MAD

    Time frame: MAD phase: Day 1 to Day 120

  17. C(336H) Accumulation Index; ratio of C(336H) at steady-state to C(336H) after the first dose (AI 336H) for MAD

    Time frame: MAD phase: Day 1 to Day 120

  18. Immunogenicity of single and multiple doses of BMS-986089 will be measured by testing for the presence of ADAs for SAD and MAD

    Time frame: 30 days

  19. The pharmacodynamic effect of single and multiple doses of BMS-986089 on free myostatin, total myostatin (pre-dose only), and myostatin-drug complex will be assessed by measuring these biomarkers for SAD and MAD

    Time frame: 30 days

07

Study locations

1 site
  • Wcct Global, Llc
    Cypress, California 90630, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in Feb 2016, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2014
First posted
May 22, 2014
StartActual
Jun 30, 2014
Primary completionActual
Feb 29, 2016
CompletionActual
Feb 29, 2016
Last update
Sep 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02145234
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 22, 2014
Start date
Jun 30, 2014
Primary completion
Feb 29, 2016
Completion
Feb 29, 2016
Last update
Sep 7, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taldefgrobep alfa

Start the discussion